drugset / Trial / NCT00649181

Fasting Study of Metolazone Tablets 5 mg and Zaroloxyn® Tablets 5 mg

NCT00649181

Phase 1 Completed 52 enrolled Mylan Pharmaceuticals Inc
RandomizedCrossoverOpen-labelOther

Summary

The objective of this study was to investigate the bioequivalence of Mylan metolazone 5 mg tablets to Celltech Zaroxolyn® 5 mg tablets following a single, oral 10 mg (2 x 5 mg) dose administration under fasting conditions.

Timeline

Start
2003-10
Primary completion
2003-11
Completion
2003-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Metolazone Small molecule 10 mg Oral

Indications

No indication recorded.